West Pharmaceutical VP awarded shares, some withheld

West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported two stock transactions in company common stock.

Rhea-AI Filing Summary

West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported two stock transactions in company common stock. He acquired 115.910 shares at a stated price of $0.0000, representing shares issued from performance stock units that vested for the 2023–2025 performance period.

On the same date, 41.519 shares were disposed of at $243.1900 per share to cover tax obligations through share withholding, rather than an open-market sale. After these transactions, he directly owned 1,369.746 shares of West Pharmaceutical Services common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Witherspoon Charles

Role VP & Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	115.91	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	41.519	$243.19	$10K

Holdings After Transaction: Common Stock — 1,369.746 shares (Direct)

Footnotes (1)

1. F1. These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did West Pharmaceutical (WST) VP Charles Witherspoon report?

Charles Witherspoon reported receiving 115.910 shares of West Pharmaceutical common stock and a related withholding of 41.519 shares for taxes. These movements stemmed from vested performance stock units covering the 2023–2025 performance period, rather than open-market buying or selling activity.

How many West Pharmaceutical (WST) shares did the VP acquire in this award?

He acquired 115.910 shares of West Pharmaceutical common stock at a stated price of $0.0000 per share. The shares were issued upon vesting of performance stock units tied to the 2023–2025 performance period and became payable on the reported transaction date.

Why were 41.519 West Pharmaceutical (WST) shares disposed of in the Form 4?

The 41.519 shares were disposed of to satisfy tax liabilities linked to the vested performance stock units. This disposition occurred via share withholding at $243.1900 per share, meaning the shares were not sold in the open market but used to cover withholding obligations.

What is Charles Witherspoon’s direct West Pharmaceutical (WST) share ownership after these transactions?

Following the grant and tax-withholding disposition, Charles Witherspoon directly owned 1,369.746 shares of West Pharmaceutical common stock. This figure reflects his updated beneficial ownership after the performance stock units vested and the related tax withholding shares were surrendered.

What do the performance stock units (PSUs) represent in West Pharmaceutical (WST) VP’s filing?

The performance stock units represent equity awards that vested based on results over the 2023–2025 performance period. Once the period ended, the PSUs converted into 115.910 shares of common stock, which were delivered to Charles Witherspoon and partially used to cover associated tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 07:04 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Witherspoon Charles

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		115.91(1)	A	$0	1,411.265	D
Common Stock	02/17/2026		F		41.519	D	$243.19	1,369.746	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown.

	/s/ Louis Lalli, as an agent for Charles Witherspoon	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.